Upexi, Inc. (UPXI)
NASDAQ: UPXI · Real-Time Price · USD
0.970
+0.070 (7.73%)
At close: Mar 9, 2026, 4:00 PM EDT
0.955
-0.015 (-1.51%)
After-hours: Mar 9, 2026, 7:47 PM EDT

Company Description

Upexi, Inc. engages in the development, manufacture, and distribution of consumer products.

It offers nail grinder and healthy all-natural pet supplements under the LuckyTail brand; energy solutions under the PRAX brand; functional mushrooms under the Cure Mushrooms brand; cannabinoid under the Moonwlkr brand; and gummies and other products under the Gumi Labs brand name.

The company sells its products through direct-to-consumer network, wholesale partnerships, and third-party platform.

It also focuses on cryptocurrency industry and management of cash assets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022.

Upexi, Inc. was incorporated in 2018 and is headquartered in Tampa, Florida.

Upexi, Inc.
Upexi logo
Country United States
Founded 2018
IPO Date Jun 24, 2021
Industry Internet Content & Information
Sector Communication Services
Employees 59
CEO Allan Marshall

Contact Details

Address:
3030 North Rocky Point Drive, Suite 420
Tampa, Florida 33607
United States
Phone 727 287 2800
Website upexi.com

Stock Details

Ticker Symbol UPXI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year July - June
Reporting Currency USD
IPO Price $5.00
CIK Code 0001775194
CUSIP Number 39959A205
ISIN Number US39959A2050
Employer ID 83-3378978
SIC Code 6199

Key Executives

Name Position
Allan J. Marshall Chief Executive Officer, President and Chairman of the Board
Andrew James Norstrud CPA Chief Financial Officer and Director
Brian Benjamin Rudick C.F.A. Chief Strategy Officer

Latest SEC Filings

Date Type Title
Mar 5, 2026 8-K Current Report
Feb 17, 2026 SCHEDULE 13G/A Filing
Feb 13, 2026 SCHEDULE 13G/A Filing
Feb 11, 2026 SCHEDULE 13G/A Filing
Feb 10, 2026 8-K Current Report
Feb 10, 2026 10-Q Quarterly Report
Feb 9, 2026 8-K Current Report
Feb 9, 2026 424B5 Filing
Feb 5, 2026 8-K Current Report
Feb 4, 2026 424B7 Filing